The Eeva™ Test
Current Standard of Care in IVF
The Center for Disease Control reports that, in the United States, one out of eight couples is impacted by infertility1. Once an infertility diagnosis is received, in vitro fertilization (IVF) is a journey many couples choose to navigate. Unless you’ve been there, it’s hard to fully understand the emotional toll it takes.
Embryologists in IVF clinics have the difficult task of selecting embryos that have the best chance of implanting and developing into pregnancy. The current standard of care relies on traditional morphology, which is the subjective analysis of the visual appearance of the embryos, such as the number and symmetry of cells, and degree of cell fragmentation. Embryologists often have a difficult choice to make on which one or two embryos to transfer when there appear to be several “good/fair” embryos from which to choose.
The Eeva™ Test
The Eeva™ Test is a non-invasive, clinically validated, first-in-class test – and one of the most significant IVF breakthroughs in decades. Enabled by time-lapse imaging analysis, this prognostic test aids embryologists in the selection of embryos, which may improve IVF outcomes and make a difference in the lives of patients.
How It Works
The Eeva Test works by using time-lapse imaging to record images of embryos during the incubation period (the first 3 days after fertilization). The images are fed into a software program that uses cell division timings and parameters in order to assess which embryos have the highest development potential. The Test provides the IVF team with objective and validated information that they can use in addition to their traditional morphology observations and more confidently decide which embryos to transfer into the mother’s womb.
The Eeva results include a video of the embryo development and a report that shows the embryo evaluation and prediction of development potential for each embryo. The clinicians can share this information and show you which embryo or embryos were selected for transfer and why, taking some of the unknowns out of the IVF journey and giving you better confidence that the embryos with the very best potential have been selected.
Auxogyn is the company behind the Eeva Test and is dedicated to advancing women’s reproductive health by translating scientific discovery into clinical solutions that improve patient outcomes. The scientific foundation for its Eeva Test is based on groundbreaking research and innovation licensed from Stanford University2, which was published in Nature Biotechnology in October 2010, and further recognized for its clinical relevance as a top 10 Medical Breakthrough by TIME magazine.
The Eeva System is cleared for marketing by the FDA and should be available for commercialization in the U.S. later this year.
Auxogyn, Inc, the company behind the Eeva Test, is enrolling patients in clinical studies in the U.S. on an ongoing basis. Information about the details of each of these studies can be found here.
1. National Survey of Family Growth
2. Wong et al. Nature Biotechnology (2010)